Hetacillin
Versapen, Versapen-k (hetacillin) is a small molecule pharmaceutical. Hetacillin was first approved as Versapen on 1982-01-01. It is used to treat bacterial infections in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Hetacillin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VERSAPEN | Bristol Myers Squibb | N-050060 DISCN | 1982-01-01 | 2 products |
Hide discontinued
Labels
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | HETACILLIN |
| INN | hetacillin |
| Description | Hetacillin is a penicillin. It has a role as an antibacterial drug. It is a conjugate acid of a hetacillin(1-). |
| Classification | Small molecule |
| Drug class | penicillins |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC1(C)S[C@@H]2[C@H](N3C(=O)[C@@H](c4ccccc4)NC3(C)C)C(=O)N2[C@H]1C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 3511-16-8 |
| RxCUI | 26797 |
| ChEMBL ID | CHEMBL1201116 |
| ChEBI ID | 5683 |
| PubChem CID | 443387 |
| DrugBank | DB00739 |
| UNII ID | TN4JSC48CV (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:

Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 121 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions

Mock data
Subscribe for the real data
Subscribe for the real data
1 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more
